Marinus Pharmaceuticals Inc
NASDAQ:MRNS
| Market Cap (Intraday) | 712.48M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $17.48 |
| 50-Day MA | $15.47 |
| 200-Day MA | $13.97 |
Marinus Pharmaceuticals Inc Stock, NASDAQ:MRNS
5 Radnor Corporate Center, 100 Matsonford Road, Radnor, Pennsylvania 19087-5279
United States of America
Phone: +1.484.801.4670
Number of Employees: 72
Description
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.